MicroRNAs (miRNAs) function as either oncogenes or tumor suppressors by inhibiting the expression of target genes, some of which are either directly or indirectly involved with canonical signaling pathways. The relationship between miRNAs and signaling pathways in gastric cancer is extremely complicated. In this paper, we determined the pathogenic mechanism of gastric cancer related to miRNA expression based on recent high-quality studies and then clarified the regulation network of miRNA expression and the correlated functions of these miRNAs during the progression of gastric cancer. We try to illustrate the correlation between the expression of miRNAs and outcomes of patients with gastric cancer. Understanding this will allow us to take a big step forward in the treatment of gastric cancer.
INTRODUCTION
Gastric cancer is the fourth most common cancer and the second leading cause of cancer-related death in the world. 1 There are B1 million new patients diagnosed with gastric cancer every year. 2 Gastrectomy is the mainstay treatment for gastric cancer; however, early diagnosis is very difficult in clinics and the prognosis for advanced-stage patients is still very poor. 1 There will be a significant improvement in the diagnosis and treatment of gastric cancer if the relationships between oncogenesis, development and prognosis are much better understood.
The complex interactions that take place among different etiological factors lead to genetic and epigenetic alterations of proto-oncogenes and tumor-suppressor genes; a basic paradigm underlying the pathogenesis of any cancer. Dysregulation of these genes results in abnormal function or expression of oncogenic and tumor-suppressor proteins. Accumulating evidence indicates that microRNAs (miRNAs) are involved in important biological processes related to apoptosis, proliferation, differentiation, metastasis, angiogenesis and the immune response, dysregulation of which is crucial to cancer initiation, progression and treatment outcomes. Expression of miRNAs has been shown to be related to gastric cancer as well as other cancers and plays important roles in regulating cancer-related genes. 3, 4 The miRNAs act as posttranscriptional regulators of gene expression that could regulate 430% of the protein-coding genes in the human genome. 5 This class of RNAs was identified through investigation of Caenorhabditis elegans. 6, 7 Up till now, 1872 precursors and 2578 mature forms of human miRNAs have been discovered in accordance with the publication of miRBase version 20.0 (http://www.mirbase.org/). It is strongly believed that the amount of miRNAs and the ways in which they function are much more complex than expected.
We try to determine the progress of gastric cancer research related to miRNA expression based on studies performed in recent years and reviews of the regulation network and correlated functions of these miRNAs. A better understanding of miRNAs in gastric cancer may be achieved through the review of this literature that will thus give rise to new avenues of research.
THE miRNA BIOGENESIS AND FUNCTION
The miRNAs are small noncoding RNAs that are B22 nucleotides in length. To date, more than 2000 miRNAs have been identified in humans. In the nucleus, a primary miRNA of several kilobases is transcribed from the miRNA gene by RNA polymerase II/III. 8, 9 After transcription, the ribonuclease enzyme Drosha, coupled with its binding partner DGCR8, excises one or more B70-nucleotide stem-loop structures from the primary miRNA to form precursor miRNA. 10 The precursor miRNA is then transported into the cytoplasm by the Ran-GTP-dependent nuclear export factor, Exportin-5. 11 In the cytoplasm, Dicer processes the precursor miRNA and generates a B22-nucleotide RNA duplex that contains both the mature miRNA strand and its anti-strand. 12 The mature stranded miRNA is incorporated into the RNA-induced silencing complex that targets complementary sequences in the 3 0 -untranslated region of mRNAs, thereby functioning as a means to cleave mRNA or inhibit its translational function. 13, 14 Afterward, the complementary strand is usually rapidly degraded 15 ( Figure 1 ).
DYSREGULATED miRNAs IN GASTRIC CANCER
There are an increasing number of studies demonstrating the overexpression or downregulation of specific miRNAs in gastric cancer, and these are listed in Table 1 . There have been many studies regarding miRNA functions in gastric cancer. Some miRNAs exhibit downregulation as tumor suppressors (listed in Table 2 ), whereas others exhibit upregulation as oncogenes (listed in Table 3 ). Furthermore, some miRNAs have displayed conflicting functions in different studies (listed in Table 4 ), thereby indicating that more research is needed.
THE miRNAs AND SIGNALING PATHWAYS IN GASTRIC CANCER
In the process of tumorigenesis and the development of gastric cancer, miRNAs function as either oncogenes or tumor suppressors by inhibiting the expression of target genes, some of which are involved in canonical signaling pathways either directly or indirectly. The results of recent studies regarding these activities are reviewed herein.
PI3K/Akt pathway
The phosphatidylinositide 3-kinase (PI3K)/Akt pathway has been implicated in cancer since the discovery of its enzymatic activity associated with viral oncoproteins 20 years ago. However, in the past 10 years, it has become apparent that this pathway is one of the most frequently mutated pathways in all spontaneous human tumors. PI3Ks belong to a conserved family of lipid kinases that phosphorylate the 3 0 -hydroxyl group of phosphoinositides. 133 There are three classes of PI3Ks grouped according to their substrate preference and sequence homology, but only class IA PI3Ks are implicated in human cancers. The most well-characterized product of this reaction is phosphatidylinositol-3,4,5-trisphosphate or PIP3, a critical second messenger that recruits AKT for activation of growth, proliferation and survival signaling. 134 PIP3 is negatively regulated through dephosphorylation by the tumor-suppressor phosphatase and tensin homolog (PTEN). Class IA PI3Ks are heterodimers comprising a regulatory subunit (p85a, p55a, p50a,p85b, p55g) and a catalytic subunit (p110a, p110b, p110d) and are activated downstream of receptor tyrosine kinases. 135 PTEN is a tumor-suppressor gene and its role in tumor biology is well characterized. 136 Inactivation of PTEN leads to the activation of AKT through accumulation of PIP3. Moreover, pAkt is a crucial protein involved in the regulation of cell cycle progression, cell survival, apoptosis, invasion and radiosensitivity. The PTEN gene is an important functional target of the miRNA-221/222 cluster in gastric cancer cells. Modulation of miRNA-221/222 expression by antisense or overexpression strategies directly affects PTEN expression. 89 PTEN is also one of the target genes of miRNA-21 that increases the proliferation and invasion of gastric cancer cells. 92 MiRNA-214 has displayed similar effects.
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Macrophage migration inhibitory factor (MIF) promotes gastric epithelial cell proliferation through the PI3K/Akt pathway. 137 Expression of MIF has been shown to be targeted by miRNA-451, the expression of which is downregulated in gastric cancer. Restoration of miRNA-451 expression downregulates MIF and decreases expression of reporter genes with MIF target sequences in gastric cancer cells that is accompanied by a reduction in cell proliferation and an enhancement of cell death in response to irradiation. 31 MiRNA-375 suppresses the PI3K/Akt pathway through direct targeting of PDK1, a kinase that phosphorylates Akt. This is yet another miRNA that regulates the activity of the PI3K/Akt pathway. Ectopic expression of miRNA-375 substantially reduces cell viability through induction of the caspase-dependent apoptotic pathway 23 ; microarray analysis has revealed that miRNA-375 is one of the most downregulated miRNAs in gastric cancer. Finally, other research has indicated that miRNA-143 is involved in the regulation of cell function through the PI3K/Akt pathway because its target gene is Akt itself. 35 Ras/Raf/MEK/ERK pathway The Ras/Raf/MEK/extracellular-signal-regulated kinase (ERK) pathway is another important pathway that plays a fundamental role in the regulation of cell proliferation and survival as well as in human tumorigenesis. The Ras/Raf/MEK/ERK pathway is a central signal transduction pathway that transmits signals from multiple cell surface receptors to transcription factors in the nucleus. 138 This pathway is frequently referred to as the MAP kinase pathway as MAPK stands for mitogen-activated protein kinase, thereby indicating that this pathway can be stimulated by mitogens, cytokines and growth factors. The pathway is activated by membrane translocation of Raf stimulated by Ras. Three members of the RAS family (HRAS, KRAS and NRAS) are found to be activated by mutation in human tumors. 139 Hashimoto et al. 48 demonstrated that reduced expression of miR-181c may play an important role 184 Gastric cancer tissues and 169 nontumor mucosae miR-181d, miR-181a-1, miR-181a-2, miR-181c, miR-181b-1, miR-181b-2, miR-21, miR-25, miR-92-1, miR-92-2, miR-93, miR-17-5p, miR-106a, miR-20b, miR135a-1, miR-135a-2, miR-425-5p, miR-106b, miR-20a, miR-19b-1, miR-19b-2, miR-224, miR-18a, miR-135b, miR-19a, miR-345, miR-191 miR-148a, miR-148b, miR-375, miR-29b-1, miR-29b-2, miR29c, miR-152, miR-218-2, miR-451, miR-30d, miR-30a-5p, miR-30b, miR-30c-1, miR-30c-2, miR-422b miR-623, miR-134, miR-181c(a), miR-654-5p, miR-936, miR-939, kshv-miR-K12-3, miR-550, miR-486-5p, miR-575, hcmv-miR-UL70-3p, miR-638, hsv1-miR-H1, miR-139-3p, miR-202, miR-378, hsv1-miR-LAT, miR-596, miR-188-5p, miR-28-3p, miR-30d, miR-572, miR-1225-5p, miR-345, miR30a, miR-671-5p, hiv1-miR-H1, miR-148a(a), miR-222, miR10b(a), miR-564, miR-193b(a), miR-125a-3p, miR-370, miR-375, miR-923, miR-513c, miR-513a-5p, miR-494, miR-513b in gastric carcinogenesis through KRAS overexpression. There are at least three Raf gene families that have been confirmed to be present in eukaryotic cells: Raf-1, A-Raf and B-Raf. Activation and inactivation of Raf-1 is complex and involves multiple kinases and phosphatases as well as the GTP/GDP exchange protein Ras and members of the Rho family of GTPases including RhoA, Rac1 and Cdc42. 140 A group of Chinese researchers demonstrated that miRNA29s could effectively inhibit protein expression/phosphorylation of In research regarding blood diseases, such as leukemia, it has been found that the Ras/Raf/MEK/ERK pathway exerts its effects on cell cycle progression through the induction of cell cycle regulatory proteins including CDKs, cyclins and p21
Cip1 , and transcription factors including NF-kB, c-Myc, Ets, CREB and AP-1. [141] [142] [143] Previous research has demonstrated that many of the factors in the Ras/Raf/MEK/ERK pathway are miRNA target genes and can interact with miRNAs. Cyclin D and cyclin E that bind to CDK4/6 and CDK2, respectively, are important gap 1 (G1) cyclins that are rate-limiting for S-phase entry. After entering the S phase, expression of cyclin E becomes reduced but increased levels of cyclin A2 maintain CDK2 activity. The CDK2-Cyclin A2 complex is active during both S and gap 2 (G2) phases and an elevation in CDK1-cyclin B activity in the late G2 phase triggers progression to mitosis.
144 CDK6 is a cyclin-D1-dependent kinase that phosphorylates the retinoblastoma protein, thereby removing repression of E2F transcription factor activity and influencing cell cycle progression. 145 Feng et al. 126 demonstrated that CDK6 is regulated by miRNA-107 in gastric cancer. The expression of miRNA-107 is significantly decreased in gastric cancer and re-expression of miRNA-107 in gastric cancer cells significantly decreases proliferation. In other research, it was found that miRNA-206 is involved in gastric cancer proliferation, potentially via direct modulation of the downstream MiRNA and signaling pathways in gastric cancer Z Zhang et al target Cyclin D2. 74 MiRNA-106b and miRNA-93, both of which are upregulated in gastric cancer and are downstream targets of the oncogenic transcription factor E2F1, directly target p21 and thus impair the tumor-suppressive activity of transforming growth factor-b. 39 E2F1 was verified to be a promising target gene of both miRNA-331-3p and miRNA-106a, thereby modulating the G1/S transition. 42, 99 The former, miRNA-331-3p, exhibits action as a tumor suppressor whereas the latter does the opposite. Cho et al. 94 have confirmed that miRNA-372 is expressed in human gastric cancer AGS cells and its expression supports the growth of these cells through downregulation of the tumor suppressor LATS2. However, previous reports suggest that overexpression of LATS2 results in cell cycle arrest at the G2/M phase via inhibition of Cdc2-Cyclin B kinase activity. 146 The p42.3 gene is the target gene of miRNA-29a and one result indicated that p42.3 silencing could alter the expression of two key proteins that are involved in cell cycle regulation: CHK2 and cyclin B1. 52 The activities of CDK (cyclin-dependent kinase) are regulated by a class of molecules known as CDK inhibitors. Currently, CDK inhibitors are composed of the p16 family members (p15, p16, p18 and p19) 147 and the p21 family members (p21, p27, p28 and p57). 148, 149 Kim et al. 19 reported that miRNA-106b-93-25 and miRNA-222-221 clusters suppress the p21 family of CDK inhibitors, and specifically that miRNA-25 targets p57 through the 3 0 -untranslated region. In addition, miRNA-106b and miRNA-93 control p21, whereas miRNA-222 and miRNA-221 downregulate both p27 and p57. P27 has been verified to be a direct target of miRNA-148a, thereby suggesting that miRNA-148a might promote gastric cell proliferation by suppressing p27 expression. 123 MiRNA-196a is upregulated in gastric cancer tissues and cell lines and high expression of miRNA196a is significantly associated with tumor size, poor pT stage, pN stage and patients' overall survival times. Moreover, downregulation of miRNA-196a suppresses gastric cancer cell proliferation both in vitro and in vivo by targeting p27 kip1 . 114 Nuclear factor (NF)-kB is an important transcription factor involved in a variety of tumorigenic mechanisms. 150 Experimental evidence indicates that miRNA-9 targets NF-kB1 and regulates the growth of gastric cancer cells. 32 Overexpression of miRNA-218 also inhibits NF-kB transcriptional activation as well as transcription of cyclooxygenase-2, a proliferative gene regulated by NF-kB. 40 In another study, the biological relevance of OLFM4 as a miRNA-486 target was supported by evidence that OLFM4 silencing can reduce proliferation of gastric cancer cells, and that OLFM4 overexpression can rescue the antioncogenic effects of miRNA-486. 26 MiRNA-429 plays a role in the pathogenesis of gastric carcinoma and may function as a recessive cancer gene. C-Myc is a transcription factor that is an important miRNA-429 target gene. 56 According to work published by Xu et al., 46 it may be one of the targets of miRNA-212.
The Ras/Raf/MEK/ERK pathway and Raf by itself also have diverse effects on key molecules involved in the prevention of apoptosis. It has been revealed that the Ras/Raf/MEK/ERK pathway can phosphorylate Bad on S112 that contributes to its inactivation and subsequent sequestration by 14-3-3 proteins. 151 This allows B-cell lymphoma 2 (Bcl-2) to form homodimers and generate an antiapoptotic response. Activation of the Raf/MEK/ERK cascade can also result in phosphorylation of the antiapoptotic Mcl-1 (myeloid cell leukemia 1) protein and the proapoptotic Bim protein. Phosphorylation of Bim results in its disassociation from Bcl-2, Bcl-XL and Mcl-1, after which Bim becomes ubiquitionated and targeted to the proteasome. This allows Bcl-2, Bcl-XL and Mcl-1 to bind Bax and prevent Bax activation as well as the formation of Bax: Bax homodimers, thus inhibiting apoptosis. [152] [153] [154] Depending on the cell type as well as the stimuli used to induce apoptosis, Raf can function as either an inhibitor 155 or a promoter 156 of apoptosis.
The execution of mitochondria-mediated apoptosis is mainly governed by opposing activities of proapoptotic (Bax, Bak, Bik, Bim, Bad, Bid, HRK, NOXA, PUMA, BNIP3 and BNIP3L) and antiapoptotic (Bcl-2, Bcl-xL, Bcl-w, A1 and Mcl-1) members of the Bcl-2 family. MiRNA dysregulation has been shown to regulate apoptosis by altering the expression of Bcl-2 family members in gastric cancer. The miRNA-106b-25 cluster protects gastric cancer cells from apoptosis. Bim, the farthest downstream apoptotic effector of the transforming growth factor-b pathway, 157 is a key target of miRNA-25. 27 Overexpression of miRNA-130b has also been reported to suppress transforming growth factor-b-induced Bim expression and apoptosis by targeting RUNX3 in gastric cancer cells. 101 Several miRNAs, including miRNA-15b, miRNA-16, miRNA-34, miRNA-181b and miRNA-497, have been shown to directly target the antiapoptotic protein Bcl-2 and regulate apoptosis. 28, 30, 67, 100 One finding suggests that the miRNA-200bc/ 429 cluster might play a role in the development of multidrug resistance in both gastric and lung cancer cell lines, at least in part by modulating apoptosis via targeting BCL2 and XIAP. 110 Despite the mounting evidence for miRNA interaction with members of the mitochondrial apoptosis pathway, whether or not they directly interact with members of the Ras/Raf/MEK/ERK pathway has not yet been reported. Through further study of this pathway, there may be more meaningful discoveries regarding this unanswered question.
Slit/Robo signaling pathway The Slit family of guidance cues binds to Roundabout (Robo) receptors to modulate neuronal, leukocytic and endothelial migration. Mammals have three Slit proteins (Slit1-3) and four Robos (Robo 1-4) . 158 Slit2 interacts with Robo1 to mediate repulsive cues in axon guidance, 159 neuronal migration 160 and leukocyte chemotaxis. 161 Slit/Robo1 signaling is now recognized as having a paradoxical role in carcinogenesis. 162, 163 Tie et al. 41 have demonstrated that miRNA-218 coding genes are located in and transcribed together with Slit genes, which are Robo1 ligands, thus creating a negative feedback loop that regulates Slit/Robo1 signaling. They also found that Slit2, but not Slit3, interacts with Robo1 to promote gastric cancer invasion.
JAK/STAT signaling pathway Cellular responses to dozens of cytokines and growth factors are mediated by the evolutionarily conserved Janus kinase/signal transducers and activators of its transcription signaling pathway (JAK/STAT). These responses include proliferation, differentiation, migration, apoptosis and cell survival, depending on signal, tissue and cellular context. JAK/STAT signaling is essential for numerous developmental and homeostatic processes including hematopoiesis, immune cell development, stem cell maintenance, organismal growth and mammary gland development. 164 In mammals, there are four members of the JAK family and seven STATs. JAK2 is a member of the Janus family of cytoplasmic nonreceptor tyrosine kinases that also includes JAK1, JAK3 and TYK2. 165 Previous research has shown that miRNA-375 may function as a tumor suppressor that potentially regulates gastric cancer cell proliferation by targeting the JAK2 oncogene. 39 Another study showed that miRNA-135a may function as a tumor suppressor by targeting JAK2 to repress p-STAT3 activation, reduce cyclin D1 and Bcl-xL expression and inhibit gastric cancer cell proliferation. 71 Wnt/b-Catenin/Tcf signaling pathway The Wnt pathway plays key roles in development and cancer. 166 The canonically known pathway involves extracellular Wnt proteins binding to and activating membrane-bound Frizzled receptors that in turn mediate phosphorylation of Dishevelled. Through binding to Axin, Dishevelled inhibits phosphorylation of b-catenin by disrupting a complex consisting of the adenomatous polyposis coli, Axin and glycogen synthase kinase-3b proteins. Unphosphorylated b-catenin then binds to transcription factors of the T-cell factor/lymphoid-enhancer factor (Tcf/Lef) family and activates transcription of specific target genes including c-Myc, cyclin D1, gastrin and ITF-2. [167] [168] [169] [170] Scott et al. 171 revealed that miRNA-27a suppresses expression of ZBTB10 mRNA that could potentially inhibit gastrin expression by interfering with Sp1 activation. Expression and activation of the Sp1 transcription factor could contribute to gastric cancer cell survival, growth and angiogenesis. 172 Another research group obtained similar conclusions in gastric miRNA research. 96 One result suggests that MAPRE1 may be a direct and functional target of miRNA-10b in gastric cancers, 66 and another study showed that MAPRE1 may also act as an oncogene in gastric cancer by activating the b-catenin/TCF pathway to promote cellular growth and inhibit apoptosis. 173 Recent studies have revealed that many proteins, such as adenomatous polyposis coli and Axin, are involved in the regulation of the Wnt signaling pathway. Therefore, miR-27 may modulate Wnt signaling by interacting with adenomatous polyposis coli. 98 
CLINICAL IMPLICATIONS OF miRNA IN GASTRIC CANCER
The miRNA polymorphisms associated with gastric cancer A miRNA mutation can be defined as a mutation that interferes with miRNA function. The miR polymorphisms/mutations can cause a gain or loss of miRNA function. Functional miR polymorphisms or mutations can create or destroy a miRNA binding site within a target mRNA and affect gene expression by interfering with the function of a miRNA. 174 Peng et al. 175 reported an association between miRNA-196a-2 gene polymorphism and gastric cancer risk in a Chinese population. Polymorphisms in miRNA-27a act as an important factor in gastric cancer susceptibility. 96, 176 Polymorphisms falling in miRNA binding sites can alter the strength of miRNA binding and disturb miRNA-mediated posttranscriptional regulation. Undoubtedly, single-nucleotide polymorphisms in some target genes may be of as much importance in gastric cancer as those located within the miRNAs themselves. Several results 177, 178 have been demonstrated to be associated with gastric cancer. For example, a polymorphism in the putative binding site for miRNA-181a within MTMR3 (rs12537CT) is associated with the susceptibility and prognosis of gastric cancer in southern Han Chinese. 115 Despite work on the polymorphic status of miRNAs and their binding sites being in its infancy, significant associations between numerous single-nucleotide polymorphisms and gastric cancer risk and onset are already coming to light. These single-nucleotide polymorphisms will be of use for the identification of a subgroup of high-risk patients, with subsequent monitoring yielding earlier tumor detection.
The miRNAs as diagnostic and prognostic markers Noninvasive tests are seeing increasing use as tools for disease diagnostics and serum/plasma miRNAs have been identified as stable blood-based markers for cancer detection. 179 Circulating methods for miRNA profiling have been suggested as a useful tool for the early diagnosis of gastric cancer. It has been demonstrated that the plasma concentrations of various miRNAs, such as miRNA-17-5p, miRNA-21, miRNA-106a and miRNA-106b, are higher whereas let-7a is lower in gastric cancer patients. The values of the area under the receiver-operating characteristic curve were 0.721 for the miRNA-106b assay and 0.879 for the miRNA-106a/let7a ratio assay in gastric cancer. 180 Three plasma miRNAs (miRNA106b, miRNA-20a and miRNA-221) were significantly elevated in gastric cancer patients as compared with healthy controls. Furthermore, in another study, areas under the receiver-operating characteristic curves using miRNA-106b, miRNA-20a and miRNA-221 for gastric cancer diagnosis were 0.7733, 0.8593, and 0.7960, respectively. 181 Quantitative reverse transcriptase-PCR analysis further identified a profile of five serum miRNAs (miRNA-1, miRNA-20a, miRNA-27a, miRNA-34 and miRNA-423-5p) as a biomarker for gastric cancer detection. 182 In another study, the biomarker for detection of early gastric cancer is another fivemiRNA panel present in plasma. 183 However, despite numerous studies, the determination of biomarkers still lacks consistency. Significant work will be required to integrate the various studies 184, 185 and enhance the sensitivity and specificity of noninvasive diagnostic tests.
Aside from the traditionary prognostic factors, miRNAs may serve as biological prognostic markers for outcome prediction as they have recently been used to predict the outcomes of patients with gastric cancer. The probability of survival was significantly lower in patients with high expression levels of miRNA-20b or miRNA-150. A correlation was found between miRNA-27a and lymph node metastasis. 18 24 reported that low expression of let-7g and miRNA-433 and high expression of miRNA-214 was associated with unfavorable outcomes in overall survival independent of clinical covariates including depth of invasion, lymph node metastasis and stage. A seven-miRNA signature is closely associated with relapse-free and overall survival among patients with gastric cancer. A patient's prognostic signature could be applicable to future decisions concerning treatment. 189 The miRNAs as therapeutic molecules The ability of miRNAs to regulate cellular processes and the aberrant dysregulation of their expression levels in cancer illustrate the potential of miRNA modulation as a viable therapeutic strategy and a powerful intervention tool. By virtue of their ability to target multiple genes and their aberrant perturbations in widespread cancers, miRNAs have emerged to be promising, novel therapeutic targets and intervention tools.
There are two main strategies for targeting miRNA expression in cancer. Direct strategies involve the use of oligonucleotides or virus-based constructs to either block the expression of an oncogenic miRNA or to reintroduce a tumor-suppressor miRNA lost in cancer. Indirect strategies involve the use of drugs to modulate miRNA expression by targeting their transcription and their processing. For example, reintroduction of miRNA-15a/16-1 induced apoptosis in leukemic MEG01 cells and inhibited tumor growth in vivo in a xenograft model. 190 The miRNA is believed to be relatively safe and has proven to be more effective in cancer treatment in earlier studies. 191, 192 Nevertheless, up till now, no preclinical study has been carried out in gastric cancer research. At present, there are still several obstacles to overcome before clinical testing of miRNA treatment can be carried out, such as delivery of miRNA to a specific tissue or disease site, avoidance of off-target effects, optimization of dosing and minimization of the likelihood of immune activation.
CONCLUSIONS AND FUTURE PROSPECTS
Over the past decade, evidence of the crucial role of dysregulated miRNAs in the pathogenesis and progression of human gastric cancer has rapidly accumulated. This thereby holds tremendous potential for progress in the development of diagnostic and therapeutic strategies for managing gastric cancer. Dysregulation of miRNAs occurs in gastric cancer as well as in other malignant diseases through numerous and complex mechanisms whereby miRNAs take part in tumor promotion and progression. However, most of these mechanisms converge on common signaling pathways that govern cell proliferation, apoptosis and invasiveness.
Past studies 193, 194 have attempted to shed light on the complex relationship between the PI3K/Akt pathway and the Ras/Raf/MEK/ ERK pathway regarding their cross-inhibition, cross-activation and pathway convergence. In addition to the independent signaling programs of these pathways that provide compensatory mechanisms, there is extensive cross-talk in both positively and negatively regulating each other. Encouragingly, co-inhibition of both pathways has proven successful in reducing tumor growth in xenograft cancer models. 195 Although the canonical JAK/STAT pathway is simple and direct, pathway components either regulate or are regulated by members of other signaling pathways including those involving the ERK MAP kinase and PI3K pathways. 196 This summary review has demonstrated that many signaling pathways act on the same target genes, thereby demonstrating that cross-talk exists among distinct signaling cascades. Further studies, especially in gastric cancer, are required in order to clarify these correlations.
A single miRNA usually regulates a series of target genes; meanwhile, that miRNA is also subject to regulation by those target genes. It is this reciprocal interaction that demonstrates the complexity of miRNA signaling. As summarized, many studies have shown that miRNA signaling is integrated into several crucial signaling pathways including the PI3K/Akt, Ras/Raf/MEK/ERK, Slit/ Robo, JAK/STAT and Wnt/b-Catenin/Tcf pathways. As of now, there has been no investigation published on the relationships between miRNAs and other signaling pathways including the Hedgehog signaling pathway and the Hippo pathway in gastric cancer.
As major regulators of cell survival, proliferation and motility, the Ras/ERK and PI3K/mTORC1 (mammalian target of rapamycin complex 1) pathways are commonly activated during oncogenesis. Owing to cross-activation and pathway convergence, the resulting activation of Ras/ERK and PI3K/mTOR signaling could theoretically facilitate the development of resistance to therapeutics targeting only one pathway. Indeed, concurrent KRAS/BRAF and PI3K/PTEN mutations reduce the cytostatic response of cancer cell lines to AKT and mTOR inhibitors. 197, 198 Furthermore, chronic treatment of melanoma cells harboring activating BRAF V600E mutations can induce resistance via Raf isoform switching and upregulation of the MAPKKK COT (also called TPL2) and IGF1R/ PI3K/AKT signaling pathways. [199] [200] [201] Tumor samples from phase I clinical trials with Raf inhibitors also exhibit NRAS mutations and platelet-derived growth factor receptor upregulation. 202 Encouragingly, treatment with inhibitors to both pathways has been found to kill resistant melanoma lines and effectively inhibit tumor growth in prostate and lung cancer mouse models. 199, 203, 204 The overall review of miRNAs in gastric cancer is an exciting one as significant progress has been made in this field over the past few years. There is no doubt that the relationship between miRNAs and signaling pathways in gastric cancer is complicated but new pieces of the puzzle are rapidly being uncovered. Further investigation into the correlation between the expression of miRNAs and outcomes in gastric cancer patients may clarify the regulation network and make big steps forward in the treatment of cancer.
